Avacta Group PLC

Research Avacta Group PLC (AVCT) on Bullrun: market cap GBX 37.02B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerAVCT
• ExchangeLSE
• CountryUnited Kingdom
• SectorHealthcare
• IndustryBiotechnology
• CurrencyGBX
• Market capGBX 37.02B
• Financial periodFY2024
• RevenueGBP 113.00K
• Revenue growth-96.0%
• Net income-GBP 52.84M
• Free cash flow-GBP 23.94M
• Gross margin100.0%

Valuation Snapshot

latest market cap is GBX 37.02B.

About Avacta Group PLC

Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. The company's lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities.

Frequently asked questions

What is Avacta Group PLC's market cap?

Avacta Group PLC's market capitalization is GBX 37.02B.

What does Avacta Group PLC do?

Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally.